SMS 201-995 and variceal haemorrhage.
Sandostatin (SMS 201-995) was evaluated in the treatment of variceal bleeding in 9 patients with liver cirrhosis and portal hypertension who were undergoing injection sclerotherapy following a variceal haemorrhage. SMS 201-995 reduced directly recorded intravariceal pressure by 38%, whereas reductions in the wedged hepatic venous pressure were around 17%. These observations suggest that SMS 201-995 may prove useful in treating bleeding oesophageal varices in the acute situation. Preliminary, promising data are shown in the results of a randomized controlled clinical trial in which SMS 201-995 plus injection sclerotherapy vs injection sclerotherapy are compared in patients with bleeding oesophageal varices. Furthermore, in experimental work associated stimulating effects of SMS 201-995 are shown on the function of the reticulo-endothelial system both in the liver and peripherally. These effects may prove useful by reducing the effects of endotoxaemia and possibly result in arresting further liver damage.
D000818:Animals; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004932:Esophageal and Gastric Varices / Q000188:drug therapy* / Q000209:etiology / Q000628:therapy; D006471:Gastrointestinal Hemorrhage / Q000188:drug therapy* / Q000209:etiology / Q000628:therapy; D006801:Humans; D006975:Hypertension, Portal / Q000150:complications / Q000188:drug therapy; D008103:Liver Cirrhosis / Q000150:complications; D015282:Octreotide; D011897:Random Allocation; D012597:Sclerosing Solutions / Q000627:therapeutic use; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
D012597:Sclerosing Solutions; D013004:Somatostatin; D015282:Octreotide